← Leaderboards
Bolni Marius Nagalo
Mayo Clinic Arizona
$2,044,070
Attributed
$2,044,070
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,044,070 · 2
By mechanism
DP2$1,377,000 · 1
K01$667,070 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Arizona
Same institution · by research overlap
- Mitesh Borad$4,321,070
- Ali Khademhosseini$21,426,218
- Rahmi Oklu$9,676,744
Others in their field
Other Emerging Leaders on “Viral”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$160,855,334
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,911,178
- John Damon Chodera · Sloan-Kettering Inst Can Research$51,025,260
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- Thomas Denny · Duke University$37,546,967
Research focus
ViralGlycoproteinsOncolysisVectorOncolytic VirotherapyImmuneHigh RewardInnovationPublic Health RelevanceTumorCarcinogenesisSafetyOncolytic VectorImmune Checkpoint InhibitorCellsBaseBacteriaAblationAttenuatedAsian AmericansAdenovirus VectorCyclic GmpCarcinomaAffect
Grant awards (6)
Novel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic Cancer$1,377,000
DP2 · FY2024 · CA · contact PI
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma$128,305
K01 · FY2022 · CA · contact PI
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma$128,305
K01 · FY2021 · CA · contact PI
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma$128,305
K01 · FY2020 · CA · contact PI
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma$128,305
K01 · FY2019 · CA · contact PI
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma$153,850
K01 · FY2018 · CA · contact PI